Geode Capital Management
GPCR icon

Geode Capital Management’s Structure Therapeutics GPCR Stock Holding History

Geode Capital Management’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.22M Buy
97,183
+29,321
+43% +$1.3M ﹤0.01% 2893
2026
Q1 		$3.27M Buy
67,862
+12,714
+23% +$870K ﹤0.01% 2932
2025
Q4 		$3.84M Sell
55,148
-2,810
-5% -$115K ﹤0.01% 2909
2025
Q3 		$1.62M Buy
57,958
+3,777
+7% +$75.2K ﹤0.01% 3254
2025
Q2 		$1.12M Buy
54,181
+8,444
+18% +$186K ﹤0.01% 3287
2025
Q1 		$792K Buy
45,737
+32
+0.1% +$784 ﹤0.01% 3384
2024
Q4 		$1.24M Buy
45,705
+480
+1% +$17K ﹤0.01% 3290
2024
Q3 		$1.98M Buy
45,225
+312
+0.7% +$12.1K ﹤0.01% 3131
2024
Q2 		$1.76M Buy
44,913
+16,017
+55% +$658K ﹤0.01% 3155
2024
Q1 		$1.24M Buy
28,896
+6,702
+30% +$283K ﹤0.01% 3283
2023
Q4 		$905K Buy
22,194
+14,403
+185% +$825K ﹤0.01% 3394
2023
Q3 		$393K Sell
7,791
-2,466
-24% -$79.5K ﹤0.01% 3690
2023
Q2 		$426K Buy
+10,257
New +$287K ﹤0.01% 3704

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Geode Capital Management's GPCR Position: Q2 2026 in Review

Geode Capital Management increased its Structure Therapeutics (GPCR) stake by 43% in Q2 2026, buying an estimated $1.3M and bringing the position to 97,183 shares worth $5.22M. The position accounts for ﹤0.01% of the portfolio, ranked #2893.

Geode Capital Management first reported a position in GPCR in Q2 2023 and has held it in 13 quarters since. 192 funds tracked by Wall St. Rank hold GPCR as of Q2 2026.

  • Geode Capital Management held 97,183 shares of Structure Therapeutics worth $5.22M as of Q2 2026.
  • Geode Capital Management bought 29,321 Structure Therapeutics shares in Q2 2026, an estimated $1.3M.
  • Structure Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #2893 holding.
  • Geode Capital Management first reported a position in Structure Therapeutics in Q2 2023 and has held it in 13 quarters since.
  • 192 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.